1ST Allergy, Asthma and Pediatrics Too, INC.
1ST Allergy, Asthma and Pediatrics Too, INC. was paid $6.82M by Medicaid between Jan 2018 and Oct 2022, across 72 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider info1ST ALLERGY, ASTHMA AND PEDIATRICS TOO, INC.
CENTENNIAL, CO 80112
CENTENNIAL, CO 80112
33aNPI1326260498assigned 05/02/2007
33bProvider typeSpecialist
28Total paid$6.82M
24GClaims151,587
24DCodes billed72
24AFirst – last monthJan 2018 – Oct 2022
Compared with peers
Next to other Specialist providers in Colorado
Rank by total paid#3 of 124
Median peer was paid$37K
This provider vs. median186×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,587 | $1.69M | |
| 2019 | 36,813 | $1.59M | |
| 2020 | 30,082 | $1.49M | |
| 2021 | 27,678 | $1.19M | |
| 2022 | 18,427 | $861K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 33,002 | 29,088 | $1.88M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 21,912 | 19,158 | $1.77M |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 8.1% | 340 | 232 | $553K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.4% | 4,175 | 3,941 | $369K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.0% | 3,193 | 2,935 | $276K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.7% | 1,933 | 1,795 | $185K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.6% | 4,497 | 4,207 | $179K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.3% | 9,400 | 8,465 | $159K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.2% | 1,929 | 1,689 | $151K |
| 95117 | 2.1% | 12,745 | 7,639 | $143K | |
| Q3014 | Telehealth originating site facility fee | 2.1% | 6,755 | 6,252 | $141K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 802 | 740 | $102K |
60 more codes
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.2% | 4,299 | $84K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.1% | 806 | $78K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 2,274 | $70K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 837 | $68K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 24 | $67K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,396 | $58K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 657 | $56K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,820 | $55K |
| 94010 | <1% | 1,524 | $43K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 363 | $42K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,079 | $37K |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 3,290 | $33K |
| 31231 | <1% | 734 | $32K | |
| 95115 | <1% | 2,091 | $18K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 450 | $17K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,293 | $16K |
| 90651 | <1% | 808 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 894 | $14K |
| 99174 | <1% | 746 | $11K | |
| 90686 | <1% | 5,278 | $11K | |
| 99000 | <1% | 3,689 | $10K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 107 | $9K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 97 | $8K |
| 92563 | <1% | 313 | $8K | |
| 90670 | <1% | 1,337 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 241 | $6K |
| 17110 | <1% | 199 | $4K | |
| 94760 | <1% | 1,867 | $4K | |
| 90734 | <1% | 259 | $3K | |
| H0049 | Alcohol and/or drug screening | <1% | 312 | $3K |
| 81002 | <1% | 866 | $2K | |
| 36416 | <1% | 954 | $2K | |
| 96401 | <1% | 57 | $2K | |
| 85018 | <1% | 784 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 659 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 75 | $1K |
| 90461 | <1% | 2,270 | $1K | |
| 90621 | <1% | 40 | $984.33 | |
| 99402 | <1% | 14 | $787.36 | |
| 81003 | <1% | 408 | $756.04 | |
| 90680 | <1% | 256 | $613.81 | |
| 90715 | <1% | 135 | $593.73 | |
| 96127 | <1% | 42 | $572.33 | |
| 90698 | <1% | 345 | $480.99 | |
| 90716 | <1% | 80 | $455.26 | |
| 90474 | <1% | 39 | $425.22 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 249 | $367.12 |
| 90619 | <1% | 14 | $356.60 | |
| 90707 | <1% | 83 | $347.91 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 14 | $340.67 |
| 92551 | <1% | 29 | $305.37 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 61 | $177.79 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 20 | $138.93 |
| 90633 | <1% | 447 | $117.89 | |
| 99050 | <1% | 14 | $101.36 | |
| 90744 | <1% | 101 | $59.40 | |
| 90685 | <1% | 319 | $44.62 | |
| 99072 | <1% | 354 | $40.00 | |
| 90647 | 0% | 39 | $0.00 | |
| 90710 | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHELMS, ERIN (BILLING MANAGER)